Authors:
Jani, AB
Vaida, F
Hanks, G
Asbell, S
Sartor, O
Moul, JW
Roach, M
Brachman, D
Kalokhe, U
Muller-Runkel, R
Ray, P
Ignacio, L
Awan, A
Weichselbaum, RR
Vijayakumar, S
Citation: Ab. Jani et al., Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era, INT J CANC, 96(6), 2001, pp. 363-371
Authors:
Valicenti, R
Lu, JD
Pilepich, M
Asbell, S
Grignon, D
Citation: R. Valicenti et al., Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the radiation therapy oncology group trials, J CL ONCOL, 18(14), 2000, pp. 2740-2746
Authors:
Werner-Wasik, M
Scott, C
Cox, JD
Sause, WT
Byhardt, RW
Asbell, S
Russell, A
Komaki, R
Lee, JS
Citation: M. Werner-wasik et al., Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC):Identification of five groups with different survival, INT J RAD O, 48(5), 2000, pp. 1475-1482